5.29
전일 마감가:
$5.45
열려 있는:
$5.47
하루 거래량:
256.90K
Relative Volume:
1.03
시가총액:
$158.34M
수익:
$50.14M
순이익/손실:
$-35.38M
주가수익비율:
-3.7786
EPS:
-1.4
순현금흐름:
$-39.46M
1주 성능:
+2.92%
1개월 성능:
-5.87%
6개월 성능:
-58.67%
1년 성능:
-33.21%
Avita Medical Inc Stock (RCEL) Company Profile
명칭
Avita Medical Inc
전화
661-568-1317
주소
28159 AVENUE STANFORD, VALENCIA, CA
RCEL을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RCEL
Avita Medical Inc
|
5.29 | 158.34M | 50.14M | -35.38M | -39.46M | -1.40 |
![]()
ABT
Abbott Laboratories
|
136.01 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
107.41 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
395.63 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
87.17 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
78.21 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-12-24 | 개시 | D. Boral Capital | Buy |
2024-04-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
2023-06-27 | 개시 | Cantor Fitzgerald | Overweight |
2021-03-02 | 개시 | Piper Sandler | Overweight |
2020-08-27 | 개시 | BofA Securities | Buy |
2020-04-21 | 개시 | Oppenheimer | Outperform |
2020-03-03 | 개시 | BTIG Research | Buy |
모두보기
Avita Medical Inc 주식(RCEL)의 최신 뉴스
(RCEL) Trading Report - news.stocktradersdaily.com
Translational Regenerative Medicine Market Is Booming So - openPR.com
Cantor Fitzgerald Predicts AVITA Medical FY2026 Earnings - MarketBeat
AVITA Medical (RCEL) Receives Continued 'Buy' Rating from D. Bor - GuruFocus
Avita Medical Says Data Show Recell Reduced Length of Hospital Stay for Burn Patients - MarketScreener
AVITA Medical Highlights Largest Real-World Analysis Demonstrati - GuruFocus
AVITA Medical (RCEL) Reports Significant Benefits of RECELL Technology in Burn Treatment | RCEL Stock News - GuruFocus
AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL | RCEL Stock News - GuruFocus
AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL - The Manila Times
New Data: Revolutionary RECELL Treatment Cuts Hospital Stays by 35%, Saves Hospitals $300M in Burn Care - Stock Titan
Cantor Fitzgerald maintains Avita Medical at Overweight, $19 target By Investing.com - Investing.com Canada
AVITA Medical's (RCEL) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
AVITA Medical (NASDAQ:RCEL) Given “Buy” Rating at D. Boral Capital - Defense World
AVITA Medical, Inc. (NASDAQ:RCEL) Short Interest Up 23.9% in May - MarketBeat
RCEL: AVITA Medical Maintains Buy Rating with $19 Price Target | RCEL Stock News - GuruFocus
Avita Medical (RCEL) Unveils Promising Results for Cohealyx in Wound Treatment | RCEL Stock News - GuruFocus
AVITA Medical’s Cohealyx shows promise in wound care - Investing.com
AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™ | RCEL Stock News - GuruFocus
AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™ - The Manila Times
AVITA Medical’s Cohealyx shows promise in wound care By Investing.com - Investing.com UK
Breakthrough: New Clinical Data Shows AVITA's Wound Treatment Heals 4x Faster Than Standard Care - Stock Titan
BNP Paribas Financial Markets Takes Position in AVITA Medical, Inc. (NASDAQ:RCEL) - Defense World
Avita Medical Stockholders Approve Key Amendments and Elections - TipRanks
Transcript : AVITA Medical, Inc.Shareholder/Analyst Call - MarketScreener
(RCEL) Investment Report - news.stocktradersdaily.com
AVITA Medical, Inc. (NASDAQ:RCEL) Shares Purchased by Ameriprise Financial Inc. - Defense World
AVITA Medical’s RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards - Yahoo Finance
AVITA Medical's RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards | RCEL Stock News - GuruFocus
No normal is the new normal - The Globe and Mail
Revolutionary Wound Care Tech RECELL Crowned Best Surgical Innovation: How 30,000 Patients Benefited - Stock Titan
Stocks in play: Fury Gold Mines Limited - The Globe and Mail
Translational Regenerative Medicine Market Is Booming So Rapidly | Athersys, Avita Medical, AxoGen - openPR.com
Deutsche Bank AG Has $292,000 Holdings in AVITA Medical, Inc. (NASDAQ:RCEL) - Defense World
Avita Medical stock hits 52-week low at $5.54 amid market challenges - Investing.com Canada
Is Abercrombie & Fitch Stock a Buy in June 2025? - The Globe and Mail
Shareholders Will Probably Not Have Any Issues With AVITA Medical, Inc.'s (NASDAQ:RCEL) CEO Compensation - simplywall.st
Jane Street Group LLC Sells 36,440 Shares of AVITA Medical, Inc. (NASDAQ:RCEL) - Defense World
Delta Investment Management LLC Buys 38,042 Shares of AVITA Medical, Inc. (NASDAQ:RCEL) - MarketBeat
(RCEL) Trading Signals - news.stocktradersdaily.com
Northern Trust Corp Raises Stock Holdings in AVITA Medical, Inc. (NASDAQ:RCEL) - Defense World
Will AVITA's Burn Care Breakthroughs Deliver A Healing Touch For Investors? - RTTNews
FY2025 EPS Estimates for AVITA Medical Boosted by Analyst - MarketBeat
Why Avita Medical, GenusPlus, Mesoblast, and Polynovo shares are storming higher - MSN
Price T Rowe Associates Inc. MD Sells 9,796 Shares of AVITA Medical, Inc. (NASDAQ:RCEL) - Defense World
Avita Medical Updates Bylaws for Governance Enhancement - TipRanks
Cantor Fitzgerald Comments on AVITA Medical FY2025 Earnings - Defense World
(RCEL) Technical Data - news.stocktradersdaily.com
AVITA downgraded by Piper Sandler over sales outlook - MSN
AVITA Medical's Acute Wound Care Showcase 2025 Streams Live Today - The Manila Times
AVITA Medical’s Acute Wound Care Showcase 2025 Streams Live Today - Yahoo Finance
AVITA Medical: Near Perfect Execution Needed To Navigate Through Balance Sheet Challenges - Seeking Alpha
Avita Medical Inc (RCEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Avita Medical Inc 주식 (RCEL) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
McNamara Robert | Director |
Feb 20 '25 |
Buy |
10.09 |
10,000 |
100,900 |
45,749 |
O'Toole David D | CFO |
Feb 20 '25 |
Buy |
9.90 |
1,000 |
9,900 |
25,734 |
O'Toole David D | CFO |
Feb 19 '25 |
Buy |
10.25 |
1,000 |
10,250 |
24,734 |
Crowe Suzanne | Director |
Dec 09 '24 |
Buy |
13.15 |
486 |
6,391 |
36,912 |
O'Toole David D | CFO |
Dec 05 '24 |
Buy |
12.46 |
975 |
12,152 |
23,734 |
자본화:
|
볼륨(24시간):